Le infezioni di cute e tessuti molli
|
|
- Coral Jenkins
- 5 years ago
- Views:
Transcription
1 Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi
2 Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance-a retrospective population based study from Finland and Sweden Jääskeläinen IH, et al. Clin Microbiol Infect 2016;22: patients; mean age 60.8 years; (60.9% male) 13.3% of patients had bacteraemia, 15.9% were admitted to an Intensive Care Unit 51% underwent at least one surgical intervention. Treatment failure occurred in 28.2%, Initial antibiotic treatment modification to another intravenous drug in 38.5% Gram-positive bacteria were predominantly isolated, Median overall LOS and antimicrobial treatment were 13 and 17 days On average 3.5 (SD 2.1) different antibiotics were used per patient. Oral antimicrobial treatment was continued in 64.3% of patients after discharge. The overall mortality rates in 30 d and in 12 m were 4.1% and 11.8%, respectively 16.4% of patients had a recurrence of SSSI within 12 months.
3 Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance-a retrospective population based study from Finland and Sweden Jääskeläinen IH, et al. Clin Microbiol Infect 2016;22:383 Comorbidities 3
4 % of patients with hospitalisation for SSTI % of patients with complications Skin and Soft Tissue Infections and Associated Complications among Commercially Insured Patients Aged 0 64 Years with and without Diabetes in the U.S. Suaya JA et al, PLoS One 2013 Apr 10;8(4):e ,227,401 SSTI episodes Diabetic patients with SSTIs* are more frequently hospitalised Diabetic patients with SSTIs more likely to be associated with complications P<0.01 P<0.01 Complications: lymphadenitis, necrotising fasciitis, gangrene, osteomyelitis, bacteraemia, septicaemia, sepsis, endocarditis
5 KEY POINTS for a discussion about TREATMENT STRATEGIES A large number recommendations have been published for the management of skin and soft tissue infections. A significant number of comparative trials has been published but they are referred to a different classifications than guidelines The empirical antibiotic therapy should take into account the patient s initial severity, the extent of infection, and the risk factors for resistant microorganisms. The prescriber should differentiate necrotizing and non-necrotizing infections, although this distinction could be difficult to apply. Optimal therapy is based on a timely and aggressive source control for severe cases
6 S. aureus - the most prevalent pathogen isolated from csssis and ABSSIs Dryden MS. J Antimicrob Chemother 2010;65(Suppl 3):iii35 iii44. 6
7 Annual visits to US Emergency Departments for selected acute bacterial skin and skin structure infections
8 MRSA-ABSSSI is associated with increased risk of mortality and healthcare costs For surgical site infections caused by MRSA vs MSSA : Patients had a 3.4 OR (95% CI: ) for 90-day mortality Patients had 5.5 days (95% CI: ) longer hospital stay Additional healthcare costs of $24,113 (95% CI: 4,521 43,704) Engemann JJ, et al. Clin Infect Dis 2003;36(5): Anderson DJ, et al. PLoS One 2009;4(12):e
9 Risk factors for MRSA-ABSSSI Multivariate ORs and 95% CIs for risk markers for MRSA SSTIs Variable Adjusted OR (95% CI) Previous MRSA infection and colonisation 6.4 ( ) Abscess 5.6 ( ) Intravenous drug use 4.6 ( ) Diabetes mellitus 4.1 ( ) Antibiotic use in prior 8 weeks 2.6 ( ) Hospital admission or surgery in previous year 2.6 ( ) Stenstrom R, et al. Can J Emerg Med 2009;11(5):
10 Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to MRSA: a plea for implementation of early switch and early discharge criteria. Eckmann C et al, Int J Antimicrob Agents 2014;44:56-64.
11 Staphylococcus aureus: Resistance Issues Methicillin Resistance Vanco MIC-creep Heterogeneous vancomycin-intermediate strains Daptomycin reduced sensitivity Rifampicin Resistance The secret world of the biofilm NEED FOR NEWS?
12 NEWS CEFTAROLINE CEFTOBIPROLE DALBAVANCIN TEDIZOLID ORITAVANCIN TELAVANCIN FOSFOMYCIN DELAFLOXACIN OMADACYCLINE
13
14
15 Setting ABSSI with sepsis signs pts Drugs CEFTAROLINE FOSAMIL (600 mg every 12 h) or VANCOMYCIN (15 mg/kg every 12 h) plus AZTREONAM (1 g every 8 h) for 5 14 days.
16
17
18 Setting ABSSI with sepsis signs pts Drugs CEFTAROLINE FOSAMIL (600 mg every 8 h) or VANCOMYCIN (15 mg/kg every 12 h) plus AZTREONAM (1 g every 8 h) for 5 14 days.
19
20
21 Setting ABSSI pts Drugs DALBAVANCIN at a dose of 1 g given intravenously over a period of 30 minutes on day 1, followed by 500 mg given intravenously over a period of 30 minutes on day 8, or VANCOMYCIN at a dose of 1 g (or 15 mg per kilogram of body weight) given intravenously over a period of 120 minutes every 12 hours for at least 3 days, with an option to switch to oral Linezolid, at a dose of 600 mg every 12 hours, to complete 10 to 14 days of therapy.
22
23
24
25 Setting ABSSI 698 pts Drugs DALBAVANCIN 1500 mg either as a single intravenous infusion or DALBAVANCIN 1000 mg IV on day 1 followed 1 week later by 500 mg IV.
26
27
28 Safety of Dalbavancin in the Treatment of SSTIs: A Pooled Analysis of Randomized, Comparative Studies. Dunne MW et al, Drug Saf 2016; 39: Data on adverse events and laboratory assessments collected from 3002 patients enrolled in seven late stage, randomized clinical trials were analyzed for patients receiving dalbavancin or a comparator antibiotic. Overall adverse event rates were similar or lower for patients receiving dalbavancin (799/1778; 44.9 %) compared with those receiving comparator agents (573/1224; 46.8 %, p = 0.012). The most common treatment emergent adverse events were nausea, headache, diarrhea, constipation, vomiting, rash, urinary tract infection, pruritus,and insomnia
29 Antibiotics currently or soon to be clinically available for infection caused by MRSA Class Agent Dose Comments Glycopeptides Vancomycin 1-1.5gm bd 15mg/kg Concern over MIC creep and resistance. Teicoplanin 400mg bd,od 6-10 mg/kg Oritavancin 1200mg sd Single dosing Similar issues as with vancomycin Dalbavancin 1500 mg sd Once weekly/ single dosing Oxazolidanones Linezolid 600mg bd Concerns about toxicity and nephropathy. Useful for IV/PO switch Tedizolid 200mg od Possibly fewer adverse events than linezolid Glycylcycline Tigecycline 100mg, then 50mgbd Concerns about safety Lipopeptide Daptomycin 4-6mg/kg Check CK (and INR if required) before treatment Beta-lactams Ceftaroline 600mg tid 1 st beta-lactam with anti-mrsa activity, Possible more rapid early clinical response. Dryden MS. Curr Opinion Infect Dis 2014;
30 EMPIRICAL 1 ST LINE MANAGEMENT of HOSPITALIZED CA-cSSTI PAIN RELATED TO CLINICAL FINDINGS DEMARCATE, SLOWLY EVOLVING PAIN UNRELATED TO CLINICAL FINDINGS NOT DEMARCATE, RAPIDLY EVOLVING NON NECROTIZING NECROTIZING? SEPSIS > SEVERE SEPSIS LRINEC SCORE > 8 AMOXI-CLAV 2.2 g/6 h +/- CLINDAMYCIN 600 mg/6 h
31 EMPIRICAL 1 ST LINE MANAGEMENT of HA- SSTI (SWI) SUPERFICIAL INCISIONAL SSI DEEP INCISIONAL SSI STERNAL WOUND INFECTION DOXYCYCLINE 100 mg/12 h + RIFAMPICIN 600 mg/24 h MICROBIOLOGY MRSA 40% MRSE >70% VANCOMICIN by CI + RIFAMPICIN 600 mg/24 h DALBAVANCIN? LINEZOLID 600 mg/12 h TEDIZOLID?
32 EMPIRICAL 1 ST LINE MANAGEMENT of HOSPITALIZED CA-cSSTI PAIN RELATED TO CLINICAL FINDINGS DEMARCATE, SLOWLY EVOLVING PAIN UNRELATED TO CLINICAL FINDINGS NOT DEMARCATE, RAPIDLY EVOLVING NON NECROTIZING NECROTIZING? SEPSIS AMOXI-CLAV 2.2 g/6 h +/- CLINDAMYCIN 600 mg/6 h > SEVERE SEPSIS LRINEC SCORE > 8 CEFTAROLINE TID / CEFTOBIPROLE for selected pts? DAPTOMYCIN for selected pts? DALBAVANCIN for home treatment/early discharge strategies? DALBAVANCIN for recurrences management?
33
LINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationNovel therapies & the role of early switch and early discharge protocols for management of MRSA infections
Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationPVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust
PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust Neonatal Case History Neonate born at 26 +2 gestation Spontaneous onset of
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationSkin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNUOVE IPOTESI e MODELLI di STEWARDSHIP
Esperienze di successo di antimicrobial stewardship Bologna, 18 novembre 2014 NUOVE IPOTESI e MODELLI di STEWARDSHIP Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Interventions
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationBest Antimicrobials for Staphylococcus aureus Bacteremia
Best Antimicrobials for Staphylococcus aureus Bacteremia I. Methicillin Susceptible Staph aureus (MSSA) A. In vitro - Anti-Staphylococcal β-lactams (Oxacillin, Nafcillin, Cefazolin) are more active B.
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationS aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium
S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of
More informationOptimizing Antibiotic Treatment of Skin and Soft Tissue Infections
Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationThe role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
More informationThe new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?
S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie
More informationBurden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital
Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationCritical impact of antimicrobial resistance
New Antibiotics Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Division of Infectious Diseases Department of Internal Medicine The Ohio State University College of Medicine Critical
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationEmpiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital
Original Article Brunei Int Med J. 2013; 9 (6): 372-377 Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Lah Kheng CHUA, Department of Pharmacy, RIPAS Hospital,
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationMeasurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist
Measurement of Antimicrobial Drug Use Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Defined Daily Dose Target Audience: Administrators and Epidemiologists Standardized definition
More informationEffectiv. q3) Purpose of Policy. Pharmacy: Antimicrobial subcommp&tittee of
Name ofpolicynupolicy:mber: Department: Approving Officer: Responsible Agent: Scope: Protected Antimicrobials 3364-133-106 Pharmacy: Antimicrobial subcommp&tittee of Chief Executive Officer Director of
More informationSKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015
SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015 Disclosures I have no financial conflicts of interest to disclose or report. Steven Tran, PharmD NEFSHP Fall Meeting 2015 Objectives for Pharmacists Review
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationSIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet
ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationDiscussion Points. Decisions in Selecting Antibiotics
Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationEmpiric therapy for severe suspected Staphylococcus aureus infection
Empiric therapy for severe suspected Staphylococcus aureus infection Salman Qureshi, MD McGill University Faculty of Medicine Department of Critical Care Medicine McGill University Health Centre Relevant
More informationRole of IV Therapy in Bone and Joint Infection
Role of IV Therapy in Bone and Joint Infection Andrew Seaton ID Consultant, Queen Elizabeth University Hospital Lead Doctor Antimicrobial Management Team, NHS GGC @raseaton66 OPAT The IVnOAT Perspective
More informationMRSA. ( Staphylococcus aureus; S. aureus ) ( community-associated )
005 16 190-194 ( Staphylococcus aureus; S. aureus ) ( community-associated ) ( -susceptible Staphylococcus auerus; MSSA ) ( -resistant Staphylococcus auerus; ) ( ) ( -lactam ) ( glycopeptide ) ( Staphylococcus
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationStaphylococcus aureus and Health Care associated Infections
Staphylococcus aureus and Health Care associated Infections Common - but poorly measured Prof Peter Collignon The Canberra Hospital Australian National University What are health-care associated infections?
More informationOne-Hit Wonders: A New Era of Antibiotics?
One-Hit Wonders: A New Era of Antibiotics? Patrick Wieruszewski, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds November 1, 2016 2016 MFMER slide-1 Objectives Identify advantages and disadvantages
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationThe Journal of Emergency Medicine, Vol. 44, No. 6, pp. e397 e412, 2013 Copyright Ó 2013 Elsevier Inc. Printed in the USA. Open access under CC BY-NC-ND license. 0736-4679 http://dx.doi.org/10.1016/j.jemermed.2012.11.050
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationConsiderations for antibiotic therapy. Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen
Considerations for antibiotic therapy Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen Infective Endocarditis There will never be a cure for this malignant disease! Sir
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationNecrotizing Soft Tissue Infections: Emerging Bacterial Resistance
Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Eileen M. Bulger, MD Professor of Surgery Harborview Medical Center University of Washington Objectives Review definition & diagnostic
More informationSepticaemia Definitions 1
Septicaemia Definitions 1 Term Definition Bacteraemia Systemic Inflammatory response (SIRS) Sepsis Bacteria that can be cultured from the blood stream The systemic response to a wide range of stresses.
More informationChoose Your Own Antibiotic/Adventure Gram-Positive Style
Disclosures Consultant for Cubist Pharmaceuticals, Inc Research support from Forest Laboratories Choose Your Own Antibiotic/Adventure Gram-Positive Style I have never seen Star Wars (But I m a big fan
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationOral antibiotics are not always straight forward
Oral antibiotics are not always straight forward OPAT Regional Workshop 1 st May 2018 Fiona Robb, Antimicrobial Pharmacist NHS Greater Glasgow & Clyde Introduction Describe NHS GGC s Oral vs IV Antibiotics
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationDrug resistant Gram positives. Dr Subramanian S MD MNAMS AB Infectious Diseases Infectious Diseases Consultant Global Health City, Chennai
Drug resistant Gram positives Dr Subramanian S MD MNAMS AB Infectious Diseases Infectious Diseases Consultant Global Health City, Chennai Flash news! Carbapenem resistant Gram negatives! Vancomycin resistant
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationTreating Complicated Skin & Diabetic Foot Infections:
Treating Complicated Skin & Diabetic Foot Infections: MRSA & the Role of Daptomycin Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP Professor of Medicine, University of Washington Director, Primary Care Clinic
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationInfectious Disease Issues in the Intensive Care Unit
Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationWho should read this document? 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version? 3
Neurosurgical infections (adult only) Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary
More informationGuidelines for the Medical management of Diabetic Foot Infection
Guidelines for the Medical management of Diabetic Foot Infection Introduction and summary points - Foot infections in diabetic patients usually begin with skin ulceration - However, skin wounds with no
More informationa SpringerOpen Journal
Szczypinska et al. SpringerPlus 2013, 2:696 a SpringerOpen Journal RESEARCH Open Access The impact of initial antibiotic therapy (linezolid, vancomycin, daptomycin) on hospital length of stay for complicated
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationyour hospitals, your health, our priority PARC (Policy Approval and Ratification Committee) STANDARD OPERATING PROCEDURE:
STANDARD OPERATING PROCEDURE: TRUST ANTIBIOTIC TREATMENT SOP SOP NO: TW10/136 SOP 1 VERSION NO: VERSION 6.1 (JANUARY 2013) APPROVING COMMITTEE: INFECTION PREVENTION AND CONTROL COMMITTEE DATE THIS VERSION
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationTreatment challenges in the management of complicated skin and soft-tissue infections B. I. Eisenstein
REVIEW Treatment challenges in the management of complicated skin and soft-tissue infections B. I. Eisenstein Cubist Pharmaceuticals, Inc., Lexington, MA and Harvard Medical School, Boston, MA, USA ABSTRACT
More informationGram-Positive Infections and OPAT:
Gram-Positive Infections and OPAT: Developments and Observations R. Andrew Seaton Gartnavel General Hospital Glasgow, Scotland, UK The views presented are the views of the speaker and not necessarily the
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationTACKLING THE MRSA EPIDEMIC
TACKLING THE MRSA EPIDEMIC Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine MRSA Trend (HA + CA) in US TSN Database USA (1993-2003) % of MRSA among S. aureus
More informationCEFTAROLINE FOSAMIL (ZINFORO )
Page 1 London New Drugs Group APC/DTC Briefing Document CEFTAROLINE FOSAMIL (ZINFORO ) Contents Summary 1 Background 3 Ceftaroline 4 Clinical efficacy 6 FOCUS 1 and 2 6 CANVAS 1 and 2 9 Health economics
More informationMRSA ventilatorassociated
MRSA ventilatorassociated pneumonia Jean Chastre, M.D. www.reamedpitie.com Conflicts of interest Consulting or lecture fees: Medimmune/Astrazeneca, Bayer, Pfizer, Arsanis, Cubist/Merck, Basilea, Aridis,
More informationDRAFT DRAFT. Paediatric Antibiotic Prescribing Guideline. May
Paediatric Antibiotic Prescribing Guideline www.oxfdahsn.g/children Magdalen Centre Nth, 1 Robert Robinson Avenue, Oxfd Science Park, OX4 4GA, United Kingdom t: +44(0) 1865 784944 e: info@oxfdahsn.g Follow
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationTherapeutic options: what s new in the pipeline?
Therapeutic options: what s new in the pipeline? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain Drug Research Institute, Université catholique de Louvain,
More information